「EGF-R」の共起表現(1語右で並び替え)

already bound an agonist (e.g., in the case of EGFR), allowing this agonist to go and stimulate a r

s the formation and activation of ErbB1/ErbB-2 ( EGFR and HER2) heterodimers that have a prominent ro

investigated for breast cancer as well as other EGFR and Her2 driven cancers.

1 cell proliferation, due to down-regulation of EGFR and inhibition of AKT and MAPK phosphorylation.

ed that even though matuzumab efficiently binds EGFR and blocks its phosphorylation, it is not as ef

losely related protein tyrosine kinases such as EGFR and its close relative HER2.

discriminate between the kinase domains of the EGFR and that of the insulin receptor.

ATP-competitive, although they are when used in EGFR as described in QSAR studies.

Mutations involving EGFR could lead to its constant activation which cou

In 2005 it was shown that inhibitors of EGFR could enhance axonal regeneration on non-conduc

each antibody may elicit different responses on EGFR downstream signalling pathways with a distinct

member of the epidermal growth factor receptor ( EGFR) family of receptor tyrosine kinases.

ein family or epidermal growth factor receptor ( EGFR) family is a family of four structurally relate

Consequently, mutations of EGFR have been identified in several types of cancer

Thus gefitinib is an EGFR inhibitor.

al to be transmitted even in the presence of an EGFR inhibitor.

The target protein ( EGFR) is also sometimes referred to as Her1 or ErbB-

2 (Her2) and epidermal growth factor receptor ( EGFR) kinases.

r for IRESSA than chemotherapy in patients with EGFR mutation positive tumours (HR 0.48, 95 per cent

Afatinib is not only active against EGFR mutations targeted by first generation TKIs lik

h affinity to epidermal growth factor receptor ( EGFR) on the cell surface and stimulating the intrin

g a mutated IGF-1 receptor to act as one of the EGFR partners in the homodimer, so forming a heterod

ssociated with epidermal growth factor receptor EGFR), RNA stabilization products with its Armored R

tion as well as cytoskeletal reorganization and EGFR signaling.

lood clotting protein fibrinogen also activates EGFR, thereby inhibiting regeneration of axons.

the Syp/PTP1D protein, Grb2 binds to activated EGFR through Shc, another adaptor protein that forms

nhibitor of epidermal growth factor receptor's ( EGFR) tyrosine kinase domain.

binds to the epidermal growth factor receptor ( EGFR) with high affinity.

「EGF-R」の共起表現一覧(1語右で並び替え)